Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy

Journal of Infectious Diseases

Volumn 203, Issue 3, 2011, Pages 364-371

  Zoufaly, A ^a   An Der Heiden, M ^b   Kollan, C ^b   Bogner, J R ^c   Fatkenheuer G ^d   Wasmuth, J C ^e   Stoll, M ^f   Hamouda, O ^b   Van Lunzen, Jan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL THERAPY; ARTICLE; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCOSIS; CRYPTOSPORIDIOSIS; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; KAPOSI SARCOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TOXOPLASMOSIS; TREATMENT OUTCOME; TUBERCULOSIS; UTERINE CERVIX CANCER; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 79751496147     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/jinfdis/jiq055     Document Type: Article

References (27)

1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-30. (Pubitemid 28534954)
2. Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60. (Pubitemid 28135961)
3. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-9.
4. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54. (Pubitemid 27255797)
5. Hughes MD, Daniels MJ, Fischl MA, KimS, Schooley RT. CD4+ cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. AIDS 1998; 12: 1823-32. (Pubitemid 28454448)
6. Battegay M, Fluckiger U, Hirschel B, Furrer H. Late presentation of HIV-infected individuals. Antivir Ther 2007; 12:841-51. (Pubitemid 47492554)
7. Borghi V, Girardi E, Bellelli S, et al. Late presenters in an HIV surveillance system in Italy during the period 1992-2006. J Acquir Immune Defic Syndr 2008; 49:282-6.
8. Wolbers M, Bucher HC, Furrer H, et al. Delayed diagnosis of HIV infection late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med 2008; 9:397-405. (Pubitemid 352015643)
9. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 2006; 20:2371-9.
10. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4+ cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-77. (Pubitemid 33096808)
11. Street E, Curtis H, Sabin CA, Monteiro EF, Johnson MA. British HIV Association (BHIVA) national cohort outcomes audit of patients commencing antiretrovirals from naive. HIV Med 2009; 10:337-42.
12. Tan R, Westfall AO, Willig JH, et al. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47:553-8. (Pubitemid 351442024)
13. Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009; 48:350-61.
14. Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4+ cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999; 13:669-76. (Pubitemid 29286701)
15. Group HSMC. Human immunodeficiency virus type 1 RNA level and CD4+ count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group. AIDS Res Hum Retroviruses 2000; 16:1123-33.
16. d'Arminio Monforte A, Testori V, Adorni F, et al. CD4+ cell counts at the third month of HAART may predict clinical failure. AIDS 1999; 13:1669-76.
17. AIDS. European Centre for the Epidemiological Monitoring of AIDS. 1993 revision of the European AIDS surveillance case definition. AIDS Surveillance in Europe. Quarterly Report 1993; 23-8.
18. Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4+ counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370:407-13. (Pubitemid 47176633)
19. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4+ T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163:2187-95. (Pubitemid 37248783)
20. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207; quiz CE1-4.
21. Levy Y. Effect of interleukin-2 on clinical outcomes in patients with CD4+ cell count 50 to 299/mm3: Primary results of the SILCAAT study [abstract 90bLB]. In: Program and abstracts of the 16th CROI, Montreal, Canada, 8-11 February 2009.
22. Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4+ cell count recovery but not clinical efficacy. AIDS 2007; 21:939-46. (Pubitemid 46684325)
23. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-106. (Pubitemid 351679596)
24. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-55.
25. Lehmann C, Jung N, Hofmann A, et al. Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression. Curr HIV Res 2008; 6:555-9.
26. Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts HIV RNA levels during follow-up. J Infect Dis 2008; 197:1145-55. (Pubitemid 351590050)
27. D'Egidio GE, Kravcik S, Cooper CL, Cameron DW, Fergusson DA, Angel JB. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count <200 cells/microl when viral replication is suppressed. AIDS 2007; 21:1711-5. (Pubitemid 47237557)